As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges. 

Our Latest News

Presenting our ESG Report

Sanofi’s ESG Integrated Report 2022 describes the progress we have made against our business-integrated CSR strategy.

Our First ESG Investor Day

In July 2022, Sanofi held its first ESG Investor Day live in its Paris HQ.

Our Double Materiality Assessment

Sanofi recently completed its first double materiality assessment to gain insights into Sanofi’s impact on the external environment and its ESG risks and opportunities and to prepare for the upcoming CSRD regulation in the European Union.

Leading the Way for Sustainable Finance

Sanofi is a pioneer of sustainable finance, with two Sustainability-linked Revolving Credit Facilities since 2020 and a Sustainability-Linked Bond, linked to its Global Health Unit, since 2021. 

Environmental, Social and Governance Performance

ESG and commercial considerations are intrinsically linked and ongoing progress in our ESG performance is vital for Sanofi to succeed and grow in a sustainable way.











Medium risk



Change: A
Water: A





New rating done in 2022









One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points

11th among 455 pharmaceutical companies

Percentile of 96 within 157 scored companies in the industry

Within the top 6 highest rated pharmaceutical companies

Leading position

1st decile of the 476 companies in the industry

With very high rating across the 3 pillars ESG

Top 10 company

1st pharma company out of 57
Score in progress since 2018

Vs previous rating
Scores assigned by the rating agencies are not equivalent.

For most recent ESG information, see also our:

Quarterly results

ESG information throughout the quarterly results presentations and in the quarterly press releases

ESG Newsletters

Bi-annual newsletter for investors with progress updates on our CSR strategy implementation.

ESG report

Chapter 4 of the French Universal Registration Document (Declaration of Extra-financial Performance)

ESG Key Performance Indicators

See our key ESG Performance Indicators

Global Reporting initiative (GRI) Index

See our GRI Index table

Sustainability Accounting Standards Board (SASB) index

See our SASB Index table

Transparency is important to us:

Our US Prescription Medicine Pricing Principles

We work passionately to prevent, treat and cure illness and disease, understand and solve healthcare needs of people across the world, and transform the practice of medicine.

Our Document Center

Find our positions on key topics, policies and Factsheets 

Quick Links

Corporate Governance

Sodium Valproate

Reports and Publications

Financial Calendar and events